IMVT vs GILD: Which Stock is Better?
Side-by-side comparison of Immunovant Inc and Gilead Sciences Inc in 2026
IMVT
Immunovant Inc
$24.50
GILD
Gilead Sciences Inc
$139.03
Key Metrics Comparison
| Metric | IMVT | GILD | Winner |
|---|---|---|---|
| Market Cap | $5.22B | $172.51B | GILD |
| P/E Ratio | N/A | 20.50 | GILD |
| EPS (TTM) | $N/A | $6.78 | GILD |
| Revenue Growth | 0.0% | 0.0% | GILD |
| Gross Margin | 0.0% | 78.8% | GILD |
Analyze IMVT
Full quant analysis
Analyze GILD
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is IMVT or GILD a better investment?
Comparing IMVT and GILD: Immunovant Inc has a market cap of $5.22B while Gilead Sciences Inc has $172.51B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between IMVT and GILD?
IMVT (Immunovant Inc) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: IMVT or GILD?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: IMVT or GILD?
GILD has higher revenue growth at 0.0% vs 0.0% for IMVT.
Which company is more profitable: IMVT or GILD?
Gilead Sciences Inc (GILD) has higher gross margins at 78.8% compared to 0.0% for IMVT.
Which is the larger company: IMVT or GILD?
Gilead Sciences Inc (GILD) is larger with a market cap of $172.51B compared to $5.22B for IMVT.
Should I buy IMVT or GILD in 2026?
Both IMVT and GILD have investment merit. IMVT trades at $24.50 while GILD trades at $139.03. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between IMVT and GILD stock?
Key differences: Market Cap ($5.22B vs $172.51B), P/E Ratio (N/A vs 20.5x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 78.8%).